STOCK TITAN

Vanguard amends 13G for 10X Genomics (NASDAQ: TXG) reporting 0 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

10X Genomics Inc ownership filing: The Vanguard Group filed an amendment to a Schedule 13G reporting 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing states Vanguard and related managed accounts have rights to dividends or sale proceeds but hold no >5% interest.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/24/2026

FAQ

What does Vanguard's Schedule 13G/A for TXG state about ownership?

Vanguard reports holding 0 shares, representing 0% of the class. The amendment clarifies that Vanguard and managed accounts have dividend or proceeds rights in general but currently do not exceed a 5% beneficial ownership threshold.

Does the filing show Vanguard controls voting or disposition for TXG shares?

No—Vanguard reports zero sole or shared voting and dispositive power. The filing lists 0 shares for sole voting, shared voting, sole dispositive, and shared dispositive power in Common Stock.

Is Vanguard acting on behalf of other investors in this Schedule 13G/A?

The filing notes Vanguard manages investment companies and accounts that may have rights to dividends or sale proceeds. It also states no other person's interest reported exceeds 5% for the securities disclosed in this amendment.

Who signed the Schedule 13G/A for Vanguard and when was it signed?

The filing is signed by Ashley Grim, Head of Global Fund Administration. The signature block shows the date 03/24/2026, attesting to the amendment's contents on that date.